title: Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment.
authors.forename: Che-Kim
authors.initials: CK
authors.lastname: Tan
authors.forename: Chih-Cheng
authors.initials: CC
authors.lastname: Lai
authors.forename: Sheng-Hsiang
authors.initials: SH
authors.lastname: Lin
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D003422:Critical Care; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D011023:Pneumonia, Staphylococcal / Q000175:diagnosis / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D014640:Vancomycin; D012293:Rifampin